In T2DM, it has been demonstratedthat edaglitazone, by activating GLP-1R, promotes insulin secretion and lowersblood glucose levels in mice, suggesting that it may be a potential GLP-1RAcandidate for the prevention and treatment of metabolic diseases like T2DM [20].In addition, prior treatment with GLP-1RAs in patients with T2DM significantlyreduced mortality following ST-segment elevation myocardial infarction (STEMI)[21]. Here, INS is linked to type 2 diabetes mellitus.